As a result, HBBplus@CA inhibited melanoma cell proliferation, migration, and invasion by simultaneously inhibiting MAPK/ERK and Wnt/β-catenin signaling pathways, providing more excellent anti-tumor activity than HBBplus or CA alone or combined treatment. Here, MAPK1 is linked to melanoma.